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4Prelude
Mijnheer de Rector Magnificus,
Ladies and Gentlemen
Kijken Denken Doen (KDD) / Look Think Do, a phrase Guus Terstappen my
dad, a surgeon, introduced to highlight a sequence that when followed
diligently provides the key ingredients to become successful in practicing
medicine, Figure 1. Before I ever opened a book on medicine it also
appeared to be a fruitful strategy to tackle normal life problems like “water
coming from the ceiling”, “no lights in the kitchen” “smoke coming out of
the engine”. Within my extended family such problems are now tackled
with the KDD principle and even those that I considered to be in possession
of two left hands are now able to solve simple problems.
Figure 1 Watercolor by Guus Terstappen showing an artistic impression of the 
tools necessary to Look, Think & Do (Kijken, Denken Doen). The Eye to 
Look, the Brain to Think and the Hand to Do.
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5While finishing up my medical degree I was witnessing a brutal procedure in
which a radiologist was poking a needle in a women’s foot for more than an
hour in an attempt to find a lymph vessel and inject contrast media to
visualize the lymph vessels draining the legs, Figure 2 Panel A. Within the
differential diagnosis was hereditary lympoedema in which case there would
be nothing to poke in. I reasoned that when I would inject a substance
subcutaneously that was too large to be taken up by the capillaries’ it would
end up in the lymph vessels. Sugars seemed harmless to me so I choose a
dextran with sufficient molecular weight coupled it to the radioactive metal
Technetium-99m, injected it into my feet and made a “lymphscintigraph”.
Figure 2 Panel B shows my lymph vessels. The patient was shown to have a
hereditary form of lymphedema and I was destined to go into science. The
KDD principles I have used ever since and the most likely reason I am
standing hear today. My scientific interests have lead me in many directions
with one common trust, identification of tools used in fundamental- and
applied science that can be put to use to solve issues faced in the diagnosis
and treatment of medical conditions. Today’s medicine is flooded with
technology and knowledge of underlying technological principles is
becoming increasingly more important to adequately practice medicine. One
of my aims is to make a contribution in the fight against cancer and believe
that collaboration between the different scientific disciplines can
significantly increase our chances to contain this disease.
Figure 2, Panel A, Feet from a patient after lympangiography,
Panel B, lymphscintigraphy showing the lymphvessels of Leon Terstappen 
after he injected his feet with TC-99m labeled dextran.
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6Introduction
Cancer is the second largest cause of death and it is becoming an
increasingly larger problem with the aging of the population. Review of the
age adjusted death rates in the USA between 1960 and 2004 shows striking
decreases in death by heart  disease, cerebrovascular disease and accidents
but only a slight improvement in death caused by cancer, Figure 3.
Figure 3 Frequency of the 10 most common causes of death in the United Stated 
between 1960 and 2004
This leads one to believe that more emphasis has been placed on tackling
cardiovascular disease or cancer is simply a much more difficult problem to
deal with. One of the impedances in tackling cancer is our lack of
understanding of the disease and the slow pace at which scientific findings
are being translated into new diagnostic tools and therapies.
Many questions arise when reviewing case histories of cancer patients.
Figure 4 shows a case history of a 38 year old woman diagnosed with breast
cancer. A routine mammogram showed a suspicious mass, and a needle
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7biopsy showed the presence of cells the pathologist deemed malignant. The
surgically removed tumor was less than one cm in diameter. The margins of
the tumor were clear of tumor and no tumor cells were detected in the
lymph nodes draining the region. The tumor grade was low and expressed
the hormone receptors estrogen and progesterone. There was no evidence of
other disease locations. No further treatment was given and the patient had
no problems until four years after surgery when she developed local pain on
her upper body. X-rays showed a suspicious mass in a rib which was
pathologically confirmed as a breast cancer metastasis. Further
investigation showed some hot spots on the bone scans, but no visceral
disease. The patient received hormonal therapy and symptoms relieved, 5
months later symptoms reappeared and a second line of hormonal therapy
was started. Disease evaluation after 3 month of therapy revealed
progression of disease with new lesions in liver and lung. The patient
received 3 lines of chemotherapy over a period of 9 months, was transferred
to a hospice and died one month later.
Observations:
1. The radiological techniques evaluate the presence or absence of a mass:
shouldn’t future technology detect the presence or absence of malignant
cells.
2. The pathological evaluation is restricted to morphological assessment of
portions of the tumor and lymph nodes: shouldn’t future technology
assess the make-up of each individual cell in the tumor and reveal its
molecular make-up.
3. At diagnosis no disease was detected beyond the primary tumor, still
tumor cells must have been present for 4 years: shouldn’t future
technology detect these dormant cells and understand what keeps them
asleep and what awakes them.
4. The choice not to administer adjuvant therapy was based on the low
anticipated risk for disease recurrence of patients with this disease
profile: shouldn’t future technology assess the dissemination of disease
and specify what systemic therapies will have a high likelihood of
success for the individual patient.
Although the need for more advanced technology in the fight against cancer
is desperately needed, we should not forget that the psychological well being
of the patient may well be of greater importance than the physical status.
Earlier this year the neurologist Prof Jan van Gijn stated during his farewell
speech “the psyche for now is an elusive brain activity that ultimately
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resides within the function of cells, their molecules and their connections”.
I believe the day will come that we uncover the secrets contained within the
cells and can explain the psychological status just like we measure the
status of other vital organs. Until that time physicians will have to take the
time to carefully listen to their patients before starting to Look, Think and
Do. The emphasis put forward by the University of Twente to support the
creation of a Chair in Medical Cell Biophysics opens the path towards this
challenging aim.
In the remaining of this lecture I will lay out the KDD strategy I have taken
during my career to address some of the questions and provide you with a
flavor of the steps needed to build the blocks required to make cancer a
chronic disease.
Before I started my PhD work, a team consisting of the biophysicists Bart de
Grooth and Jan Greve and the medical doctors Chris ten Napel, Wim van
Berkel and myself gathered to discuss malignant blood diseases and came to
the conclusion that only after we improved the understanding of normal
blood cell formation or hematopoiesis we could start to unlock the secrets
behind malignant blood cell formation. The results of these discussions were
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Figure 4 Case history of a 38 year old woman diagnosed with breast cancer.
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9written into a grant proposal and submitted to the Dutch Cancer
Foundation. The reviewers of the grant did not agree with what we believed
was a rational approach to the issue at hand and graded it as a whole lot of
baloney. Jan Greve, however, believed that we had had a good Look at the
problem, had Thought carefully and logically about the problem and decided
to use funds from the University of Twente  to let us Do the project.
So of we go.
Normal Hematopoietic Cell Differentiation
By traditional light microscopic examination of normal blood smears
erythrocytes, platelets, neutrophilic granulocytes, lymphocytes, monocytes,
eosinophilic granulocytes and basophilic granulocytes can be identified. The
large differences in frequency of these cell types make accurate and reliable
quantification difficult, Figure 5. Many diseases are accompanied by changes
in the composition of these cell types and some diseases can be recognized
based on a specific change of the peripheral blood cell composition.
Flowcytometry a technology that permits characterization of individual cells
by passing them individually at high speed through a laser beam has
accelerated the accuracy and reliability of counting different cell types and
provided us with the opportunity to uncover new information.
Figure 5 Frequency of different cell types in peripheral blood
Our contribution to this field was to measure differences in the light
scattered by the cells while passing through a laser beam. By simultaneous
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measurement of light scattered at three different angles and differences in
the polarization of the light we could identify the different peripheral blood
cell types without the need of cell staining. Figure 6 illustrates the position
of the different cell clusters in the four parameter light scatter measure-
ment 1,2. To prove that the cell clusters indeed were composed of the different
cell types a cell sorter was built that permitted conformation of the identity
of the cells in the clusters. This technology has been successfully
commercialized and I believe in today’s Dutch language the trendy name for
this process is “valorized” 3.
Figure 6 Four-parameter light scatter measure-
ment of peripheral blood leukocytes.
Panel A scatter plot of light scattered 
at an angle between 0°-2° versus 
light scattered at an angle between 
3°-11°. Gate 1 contains lymphocytes,
Gate 2 is enriched for basophils, Gate 
3 contains monocytes and gate 4 the 
neutrophilic and eosinophilic 
granulocytes. Panel B scatter plot of 
orthogonal light scatter (65°-115°) 
and depolarized orthogonal light 
scatter (65°-115° & polaroid filter 
absorbing the scattered light in the 
direction of the sample stream).
Gate 5 contains the neutrophils and 
Gate 6 the eosinophils.
In many diseases the frequency and distribution of the major blood cells is
altered, and often immature blood cells mobilized from the bone marrow
appear. The bone marrow is the source of all blood cells and it maintains the
peripheral blood cell levels at equilibrium. An amazing engine considering
the lifespan of blood cells (red blood cell ~120 days, granulocyte ~24 hours)
and the speed at which it responds to blood losses and infections. The
continuous production of blood cells is made possible by a source of cells
referred to as hematopoietic stem cells. These stem cells have the capability
to self renew as well as to differentiate into all the different types of blood
cells. By examination of morphological appearances of the different cells
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found in bone marrow, hypothesies were generated that defined
differentiation and maturation pathways that cells had to undergo, before
entering the peripheral blood. An example of a cell differentiation schema is
shown in Figure 7.
Figure 7 Hematopoietic cell differentiation, proliferation and maturation.
Mature cells are present in blood, tissue and lymphoid tissue (node).
T-lymphocyte and Natural Killer (NK) cell development reside in the 
thymus and development of other hematopoietic cells occurs in the bone 
marrow. The early hematopoietic progenitors do circulate in blood at low
frequency and can also be found in the liver4.
With the introduction of monoclonal antibody technology and fluorescence
activated flowcytometry it became possible to prove or disprove these
schemas. The monoclonal antibody HPCA-1 (CD34) made by the group of
Curt Civin was found to be expressed on approximately 1% of bone marrow
cells. Colony formation was restricted to cells expressing the CD34 antigen
suggesting that the CD34+ cells contained all hematopoietic progenitor
cells5. Evaluation of expression of different antibodies on cells expressing
the CD34 antigens yielded a typical co-expression pattern with the CD38
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antibody. The flowcytometric data display of the expression of the CD34 and
CD38 was suggestive for a differentiation pathway as illustrated in Figure 8.
Cells expressing the highest level of CD34 lacked the CD38 antigen and
represented only a small portion of the CD34+ cells. The location of these
cells in the forward and orthogonal light scatter plot suggested a
homogenous morphological appearance, generating the hypothesis that this
cell population contained hematopoietic stem cells. Cell differentiation was
thus accompanied by a gradual loss of the CD34 antigen and the acquisition
of the CD38 antigen 6,7.
Morphological examination of cells sorted along this differentiation pathway
supported the hypothesis that the cells that lacked the CD38 antigen were a
homogenous population of cells with primitive features. While cells with
increasing CD38 antigen expression were heterogeneous, and showed
features believed to be associated with cell differentiation, Figure 9 6. To
prove that these CD34+, CD38- cells were indeed hematopoietic stem cells
capable of forming all the different types of blood cells, cells present along
the differentiation pathways were sorted individually in wells which
contained media that would support their growth. Only cells within the
CD34+, CD38- cell population were capable to differentiate into all blood cell
types. Thus proving the original hypothesis, Figure 9 7.
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Figure 8 Expression of CD34 and CD38 of bone marrow cells from a healthy 
adult. PI => PIV are four regions with increasing CD38 expression that 
were used to investigate the hematopoietic cell differentiation pathway.
The cell cluster indicated with a P consists of plasma cells8 and the 
cluster indicated with IB consists of immature B-lymphocytes9.
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Figure 9 Cells in the PI => PIV gates shown in Figure 8 were sorted. Cytospins 
were made of the 4 populations and stained with Wright Giemsa.
The slides were examined on a microscope with an 100X objective and 
typical examples of the cell morphology of cells in PI, PII, PIII and PIV 
are shown in Panels A, B, C and D respectively. While the morphology of 
cells in PI and II was homogenous with features consistent with 
primitive blast, cells from PIII and PIV showed a more heterogeneous 
morphology with clear differentiation features. Individual cells of the 
PI => PIV populations were sorted into wells to which appropriate growth
media was added. Only cells in PI had the ability the generate cells 
from all hematopoietic lineages. Panel E shows a well after 10 days of 
culture showing a multiplication of the cells. Replating of these cells 
ultimately lead to differentiation of the cells into the various hema-
topoietic cell lineages. Wright Giemsa staining of the cultured cells is 
shown in Panel ---in which various cell types can be identified such as 
a macrophage (ma) a megakaryocyte (me), cells of the erythroid lineage 
(e), cells of the neutrophiloc granulocyte lineages (n) and undifferentiated
blast (b) 7.
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This work formed the basis for the mapping of the normal differentiation
pathways of each of the hematopoietic cell lineages Figure 7 6-27. With the
extensive knowledge of the normal differentiation pathways we could start
comparing normal hematopoietic cell differentiation with that found in
hematopoietic cancers.
Cancerous versus Normal Hematopoietic Cell Differentiation
Hematopoietic malignancies are traditionally identified by a predominance
of cells with similar morphological appearance in bone marrow or
lymphnodes, and subdivided into cells resembling cells of myeloid or
lymphoid origin. Questions arise at which stage of normal cell
differentiation cells derail and turn malignant. To investigate whether cell
differentiation patterns can be identified in patients with hematopoietic
malignancies the expression of CD34 and CD38 was determined in bone
marrows that were predominantly occupied by the leukemia. Figure 10
shows the relation between CD34 and CD38 expression in a bone marrow
from a normal donor and 5 patients with acute myeloid leukemia 28. The
remarkable resemblance in differentiation pathways detected in normal
bone marrow and these leukemias suggests the presence of leukemic stem
cells with similar phenotypic features as those from normal hematopoietic
stem cells. This also indicates that although the leukemia may have features
from the more mature lymphoid or myeloid lineages the actual event that
made them turn malignant is occuring at the stem cell level.
The distribution of the leukemic cells along the differentiation pathways has
implications for the prognosis. When patients were divided into those with a
predominance of cells in the early differentiation stages, in the intermediate
stages and in later stages of differentiation, a clear difference in progression
free survival was observed, Figure 11 29. Patients with a predominance of
cells in the early stages of differentiation having the worst prognosis.
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Figure 10 Expression of CD34 and CD38 on bone marrow cells from a healthy 
adult, Panel A, and 5 patients diagnosed with acute myeloid leukemia 
(AML) Panels B=>F. In Panel A the arrow starting blue and ending in red
for the lymphoid and green for the myeloid cells indicate the pathways 
along which the hematopoietic cells differentiate. A remarkable 
resemblance can be seen between the normal and malignant differen-
tiation pathways. The relative frequencies of the cells along the 
differentiation pathways are different from normal cell differentiation 
and quite different between AML patients.
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Figure 11 Kaplan Meier analysis for progression free survival of 51 AML patients.
The 22 patients with primitive cells had progression free survival of 6 
months. The 26 patients with intermediate differentiated cells had 
progression free survival of 8 months and the 19 patients with a 
predominance of mature cells had progression free survival of 
18 months.
Further characterization of these “leukemic” stem cells and their distinction
from “normal” hematopoietic stem cells can provide valuable insights that
can lead to the development of targeted therapies. Aberrant expression of
antigens is well documented in hematopoietic malignancies 30-33 opening
the door to the development of targeted therapies. First successes of targeted
therapies have already been made. For example, the aberrant expression of
the bcr-abl protein produced by the Ph chromosome in chronic myeloid
leukemia has for example lead to the development of imatinib mesylate.
This drug blocks the signal of the bcr-abl protein and drastically changed the
course of this disease. The aberrant expression of antigens can also be used
to detect residual disease. The ability to detect residual disease after
treatment allows for the determination of its effectiveness and provides a
tool to monitor the detection of early recurrence of the disease.
Simultaneous assessment of multiple parameters on both bone marrow and
peripheral blood cells have been used to demonstrate the presence of
residual leukemic cells after treatment and their presence was associated
with poor outcome 34-35. The question arises whether an earlier start of
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therapy, can prolong survival. This may not be the case for diseases for
which no or few effective therapies are available. New targeted therapies are
however emerging and may be effective upon detection of residual disease.
This will have a greater impact when specific disease mutations can be
detected in the leukemic cells and targeted therapies for these mutations
become available.
Non-Hematopoietic malignancies
The difficulty in the detection of hematopoietic malignancies in blood and
bone marrow is the discrimination from normal hematopoietic cells, which
is increasingly more difficult when the frequencies are low and the
aberrancies from normal hematopoietic cells are relatively minor. The
advantage of hematopoietic diseases is that the source is easily accessible
i.e. a blood or bone marrow aspirate can be obtained easier and more
frequently than a biopsy from a suspected lesion in a solid organ.
An important difference between hematopoietic and non-hematopoietic
malignancies is that hematopoietic malignancies remain in the
hematopoietic organs while non-hematopoietic malignancies are mostly
characterized by invasion into other organs. As a consequence cause of
death in non-hematopoietic malignancies is in most instances not caused by
the loss of function from the site the tumor arises, but through
dissemination of the disease to other organs causing their destruction. For
example, in colon cancer the organ mostly affected is the liver, in prostate
cancer the bones and in breast cancer, bone, liver and lung. A cancer cell or
an expanded group of cancer cells are relatively harmless, but become
dangerous when the cells break away from the primary site and find homes
elsewhere in the body. The cascade of events involved in the metastatic
process is shown in Figure 12. The figure depicts the penetration of tumor
cells through the surrounding tissue and blood vessel wall. The majority of
tumor cells will be trapped in the capillary beds succumb and are removed
by phagocytes. Occasionally they will adapt to the environment and
proliferate. Few tumor cells will however extravasate. Some will adapt to the
environment and either stay dormant for an undetermined period of time or
proliferate and form a metasasis. Another route tumor cells take is
penetration through the lymph vessel walls or they are simply carried away
by the draining lymph vessels. These tumor cells pass by the lymph nodes in
which they will be destroyed, multiply or simply be travelling through and
end up in the blood.
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Figure 12 Formation of metastasis. Cells in the primary tumor gain properties to 
invade the surrounding stroma and penetrate the local blood vessels.
Most of the tumor cells penetrating the blood vessels will be trapped in 
the capillary beds and are destroyed. Some will become trapped in the 
capillaries and adapt to the environment, others adhere specifically to 
molecules on the surface of the endothelial cells lining the blood vessels.
Some of these cells will extravasate, adapt to the environment and form 
micro or macro metastasis, some will persist in a dormant state and 
may be revived at a later time to give rise to a disease recurrence,
others will simply die.
Metastasis interfere with the function of organs and use up the body’s
resources and ultimately lead to death. Rarely patients die from the primary
tumor. Preventing metastasis would therefore greatly advance the fight
against cancer. Although it will not cure the disease it would make it a
chronic disease that could be managed. A more thorough understanding of
the processes involved in the escape of tumor cells from the primary tumor
is however needed. One approach is to prevent the outgrowth of blood
vessels that are needed to support the growth of the metastases as it would
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limit the supply of nutrients and oxygen to the tumors. The first therapeutic
agents taking this approach have been introduced. The therapeutic antibody
bevacizumab targeting the vascular endothelial growth factor for example
prolongs survival of patients with metastatic colorectal cancer. Only a few
factors that play a role in the metastatic process are known and a more
thorough understanding will be necessary to get a real grip on the cancer
problem.
Not only is the prevention of metastasis vitaly, but also the knowledge of
whether or not the disease has been disseminated is of great importance for
the management of the disease. The question that arises is what technology
can be used to detect the presence of tumor cells that have settled at distant
sites. The term “metastasis” was introduced by Recamier in 1829 and he
speculated that tumor cells should be present in blood 36. This was
confirmed by Ashford in 1859 37 and Engell in 1955 38 by showing the
presence of cancer cells in the peripheral blood. This spawned numerous
studies over the next twenty years and carcinocythemia and carcinoma cell
leukemia were introduced in the seventies to describe the presence of
circulating tumor cells in patients with carcinomas 39,40. The presence of
tumor cells in these case reports were associated with short survival 41-43,
but no clinical studies were performed mainly due to extremely low
frequencies of these cells and lack of standardized technology with the
necessary sensitivity and specificity to perform such studies. Observations
of tumor cells in stem cell collections used for autologous transplantation
and more advanced detection methodologies renewed attempts to identify
occult tumor cells 44-48.
After we took a good look at the problem we realized that the anticipated
frequency of tumor cells circulating in blood was to low to detect reliably
with current available technology. We believed that the frequency of
circulating tumor cells (CTC) was less than 1 cell per mL of blood which thus
needed to be found in a haystack containing at least 5 x 106 leukocytes and 
4 x 109 erythrocytes, Figure 5. We reasoned that under normal circumstances
blood should only contain cells of hematopoietic origin with maybe an
occasional endothelial cell that escaped the blood vessel wall.
The embryonic origin of blood is the mesoderm, which is separate from the
ectoderm and endoderm, all three of which are formed at the earliest phase
of the developing embryo. It can thus be expected that cell surface antigens
exist that are uniquely expressed by these three lineages and consequently
can be used to differentiate among them. Examples of antigens with an
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expression restricted to cells of epithelial origin are Epithelial Cell Adhesion
Molecule (EpCAM) a glycoprotein involved in homotypic intercellular
adhesion of epithelial cells and cytokeratins that form the cytoskeleton and
maintain the structural integrity of the cells. Likewise, the expression of the
CD45 antigen is restricted to cells of hematopoietic origin. We have used
these antigens to discriminate carcinoma cells which are of epithelial cell
origin from hematopoietic cells. Ferrofluids, with an approximate size of
~170nm, a core of Fe3O4 and coated with albumin were conjugated with
monoclonal antibodies directed against EpCAM to create immunomagnetic
ferrofluids specific for epithelial cells 49. After incubation of these ferrofluids
with 20 mL of blood and magnetic separation, the blood volume was reduced
while maintaining the epithelial cells and reducing the hematopoietic cells
with more than 4 logs. The cells were fluorescently labeled with a nucleic
acid dye, monoclonal antibodies directed against cytokeratins and CD45
were analyzed by flowcytometry. To assess whether cells of epithelial cell
origin could be detected, 20mL blood samples from healthy donors and
patients with primary and metastatic carcinomas were processed and
analyzed by flowcytometry 50. Figure 13 shows the analysis of a blood
sample from a normal donor and three carcinoma patients. The large black
dots in the figure represent epithelial cells. Two were present in blood of a
normal donor and a larger number were detected in the analysis of the
patient blood samples. The highest number were detected in blood from a
patient with metastatic breast carcinoma. The results of this study
warranted further development of this technology. However, upfront some
key observations were made that needed to be addressed before one truly
could investigate the clinical implications of the presence of CTC.
The identity of the epithelial cells needed to be confirmed as indeed being
cells and having features consistent with those of cancer cells and not
normal epithelial cells. Furthermore the sample processing needed to be
automated to avoid variable as well as erroneous results.
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Figure 13 Flowcytometric analysis of immunomagnetically enriched and 
fluorescently labeled epithelial cells from 20 mL of blood. A threshold on 
a nucleic acid dye was used to allow only events with the nucleic acid 
content of nucleated cells and gates on forward and orthogonal light 
scatter to exclude events below a size of 4µm. Panel A shows the CD45 
versus cytokeratin staining of a normal blood sample, panel B from a 
patient with organ confined breast cancer, Panel C from a patient with 
organ confined prostate cancer and Panel D from a patient with 
metastatic breast cancer. The leukocytes (CD45+, cytokeratin-) are 
depicted as small black dots, debris as small grey dots and the 
epithelial cells as large black dots50.
An instrument was designed to automate the preparation of blood samples
for CTC analysis. The configuration of the instrument is illustrated in 
Figure 14. A 7.5 mL blood sample placed on the system passes through 9
stations before the sample is placed in an analysis chamber. During the
sample processing the volume of the sample is reduced from 7.5mL to 300µl.
Erythrocytes and platelets are virtually eliminated and the leukocytes are
reduced to an average of ~5,000. The majority of the epithelial cells are
retained and the cells are stained with the DNA specific fluorescent dye
DAPI, Phycoerythrin labeled monoclonal antibodies recognizing cytokeratins
4, 5, 6, 8, 10, 13, 18 and 19 and Allophycocyan labeled monoclonal antibodies
recognizing CD45 51.
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Figure 14 Automation of isolation and labeling of epithelial cells from 7.5 mL of 
blood. Panel A shows the mechanical design of the instrument with a 
circle of 9 processing stations around a reagent reservoir. Panel B shows 
a disposable reagent tray from which the reagents are taken. Panel C 
shows the automated sample preparation instrument capable of 
processing blood samples from 8 patients in approximately 3 hours.
Panel D shows the functions for each individual station. Original 
engineering under supervision of Michael Kagen and original reagent 
development under supervision of Chandra Rao and Mark Connelly.
Now the challenge was how to analyze all the cells present in the sample.
Introduction of the sample in a flowcytometry does not permit the analysis
of the complete volume and cytospins traditionally used to prepare samples
for microscopic analysis, which are hampered with significant and variable
cell losses. We took a good look at the problem and reasoned that we should
be able to use the magnetic labels of the cells to direct them to an analysis
surface. A computer program was written to simulate the trajectories of
magnetically labeled cells in between two magnets 52. Figure 15 shows two
angled magnets with a small opening in between. The magnetic gradients
created by the magnets permitted the travel of all cells present in an
analysis chamber to its upper surface for microscopic analysis.
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Figure 15 Computer simulation of trajectory of magnetically labeled cells present 
in between two magnets. The magnets with a South and North Pole are 
angled their upper surface is spaced 3 mm apart. Each of the dotted 
lines represents the trajectory of a magnetically labeled cell. All cells 
move vertically in the middle portion below the surface of the two 
magnets. Magnetically labeled cells in a chamber placed at this position 
(red rectangular box) will thus move vertically and distribute over the 
surface forming a homogenous layer of cells. Simulations by Jerry Dolan.
A fluorescent microscope equipped with a 10X objective (NA0.45), a mercury
arc lamp, a CCD camera, a computer controlled filter wheel and X, Y, Z stage
is used to take images of the DAPI, APC and PE fluorescence covering the
complete surface of the analysis chamber. Panel A of Figure 16 shows the
140 PE images needed to cover the 2.7 mm by 33mm surface of the analysis
chamber. Panel B shows a DAPI, PE and APC image. The PE image shows a
few fluorescent events, in contrast with the DAPI and APC images, that show
many fluorescent events. Most of these events are leukocytes characterized
by a nucleus (DAPI) and CD45 staining. A computer program is used to
identify locations that fluoresce with both DAPI and PE. The two rectangular
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boxes shown in the images of Panel B represent two such events. All images
of classified events are presented to an operator that makes the final
classification. Panel C shows four events derived from a blood sample of a
metastatic carcinoma patient. The event in the top row classifies as a CTC
with a nucleus, cytoplasmic staining with cytokeratin and no staining with
CD45. The event in the second row has a nucleus, cytokeratin staining not
associated with the nucleus and staining with CD45 and classifies as a
leukocyte with some free cytokeratin in close association. The event in the
third row has a nucleus, a cytoplasm staining with cytokeratin and no CD45
staining. The event classifies as a CTC but does not appear as “healthy” as
the CTC in the top row. Two events are in the bottom row. One is a leukocyte
with a nucleus, no cytokeratin staining, but staining with CD45. The other is
a micro particle staining with only cytokeratin.
Figure 16 Analysis of the cells in the analysis chamber by fluorescence microscopy.
Panel A shows the images needed to cover the entire surface. Panel B 
shows the DAPI, PE and APC images at one position in the chamber and
the two rectangular boxes in each of the images indicates the two 
positions with DAPI as well as PE signals. Panel C shows the DAPI, PE,
APC and DAPI/PE overlap images of four events identified by the 
computer program as candidate CTC. Original software design by 
John Sylvia.
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The morphology of CTC within and between patients is extremely
heterogeneous as illustrated in Figure 17. The reproducibility of the system
was established by spiking blood of healthy donors with cells of a variety of
tumor cells expressing different levels of EpCAM and cytokeratin. The same
study showed the presence of CTC in patients with a variety of carcinomas
and an absence in blood from healthy donors 53.
Figure 17 Gallery of CTCs detected in a variety of patients. Green represents the 
cytoplasm identified by cytokeratin and purple or white the nucleus 
identified by DAPI.
To evaluate the clinical significance of CTC prospective international multi-
center clinical trials were conducted, for which patients with metastatic
breast-, colorectal- and hormone refractory prostate cancer were enrolled54-59.
Blood samples were analyzed for CTC before and at monthly intervals after
initiation of therapy. The relation between the presence of CTC before
initiation of therapy and survival of the patients is illustrated in Figure 18.
The green bars in Panels A, B and C represent the patients with zero CTC in
7.5mL of blood and the red bars patients with increasing numbers of CTC.
The percentage of represent patients in each group is indicated on top of
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each bar. Error bars indicate the 95% confidence around the median survival.
The median survival of patients with no CTC is significantly longer as
compared to those patients with one or more CTC. The survival prospects for
patients with and without CTC are remarkably similar between the three
cancers, while the proportions of patients with tumor cells detected in the
blood is quit different. The prognosis does not alter much with an increasing
number of tumor cells in the blood and only at a higher CTC number is a
decrease in survival noticed.
Figure 18 Relation between the presence of Circulating Tumor Cells and survival of
patients with metastatic breast cancer Panel A, colorectal cancer Panel B 
and hormone refractory prostate cancer Panel C before starting a new 
line of therapy. The error bars indicate the 95% confidence interval of the
median survival of the patients with the specified CTC. Original clinical 
trial designs by Gerald Doyle. Sample analysis under supervision of 
Madeline Repollet (USA) and Arjan Tibbe (Europe). Data analysis by 
Craig Miller.
For breast and prostate cancer a threshold of 5 CTC and for colorectal cancer
a threshold of 3 CTC was chosen to divide patients into those with Favorable
and those with Unfavorable CTC. The Kaplan Meier graphs in Figure 19
shows the probability of survival for metastatic breast, colorectal and
prostate cancer patients with Favorable and Unfavorable CTC at monthly
intervals after initiation of therapy. At all time points tested the difference
in survival between the Favorable and Unfavorable groups is highly
significant. Implications of these findings are that the presence of CTC are
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predictive of outcome at any time during the treatment and suggests that
the patients that have Unfavorable CTC after initiation of therapy are on a
futile therapy.
Figure 19 Kaplan Meier Analysis of overall
survival. Median overall survival 
of breast cancer patients with 
Favorable CTC after 3-5 Weeks 
(n=92), 6-8 Weeks (n=77),
9-14 Weeks (n=105) and 
15-20 Weeks (n=70) of treatment 
median was 21.7, 19.1, 20.8 and 
20.1 months. Median overall 
survival of breast cancer patients 
with Unfavorable CTC after 
3-5 Weeks (n=40), 6-8 Weeks 
(n=22) 9-14 Weeks (n= 24) and 
15-20 Weeks (n=15) of treatment 
was 6.2, 6.3, 6.4 and 11.3 months.
Median overall survival of colorectal 
cancer patients with Favorable CTC 
after 1-2 Weeks (n=316), 3-5 Weeks 
(n=292), 6-12 Weeks (n=285), and 
13-20 Weeks (n=172) of treatment was 15.7, 16.4, 15.8 and 14.6 months. Median
overall survival of colorectal cancer patients with Unfavorable CTC after 1- 2 Weeks
(n=41) 3- 5 Weeks (n=41), 6-12 Weeks (n=25), 13-20 Weeks (n=21) of treatment
median was 6.1, 4.4, 3.3 and 3.3 months. Median overall survival of prostate
patients with Favorable CTC after 2-5 Weeks (n=123), 6- 8 Weeks (n=110),
9-12 Weeks (n=100) and 13-20 Weeks (n=99) of treatment median was 20.7,
19.9, 19.6 and 19.8 months. Median overall survival of prostate cancer patients with
Unfavorable CTC after 2-5 Weeks (n=80), 6-8 Weeks (n=53), 9-12 Weeks (n=49),
13-20 Weeks (n=44) of treatment was 9.5, 8.5, 7.6 and 6.7 months.
Further Kaplan Meier analysis was performed to determine whether a
change in CTC after treatment would alter survival prospects. Patients were
divided into those that remained Favorable and Unfavorable and those that
changed to Unfavorable or to Favorable during the course of therapy,
Figure 20. Regardless of the type of cancer, patients in which CTC were not
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eliminated have an extremely poor outcome. Likewise patients that develop
CTC during the course of therapy convert from a Favorable to Unfavorable
prognosis. The data suggest that after the first cycle of therapy one already
can determine that patients with Unfavorable CTC are on a futile therapy
and other alternatives should be considered. This however represents a large
shift in the management of the disease as currently disease assessment is
performed after months of treatment and not weeks. Clinical studies are
underway to demonstrate that an early change of therapy based on
Unfavorable CTC can improve survival. Effective therapies result in an
elimination of CTC and do prolong survival as is shown by the improvement
of survival in patients of all three cancers when CTC convert from
Unfavorable to Favorable. These conversions were found after first as well as
later lines of therapies, indicating that therapies can still be effective after
previous ones have failed. Significant progress can however only be made
when we have the technology available that can tell what treatment targets
are present on the tumor cells in the individual patient at the time therapy
is to be administered and the availability of effective drugs against these
targets.
Figure 20 CTC changes after treatment of 
patients with metastatic breast,
colorectal and prostate cancer.
After initiation of therapy CTC in 
83 (47%) breast cancer patients 
remained Favorable with median 
overall survival (OS) of 22.6 months,
CTC in 39 (22%) patients remained 
Unfavorable median OS 4.1 months,
CTC in 38 (21%) patients converted 
to Favorable CTC median OS 19.8 
month and CTC converted to 
Unfavorable in 17 (10%) patients 
median OS 10.6 month. CTC in 303 
(70%) colorectal cancer patients 
remained Favorable median OS 
18.6 months, CTC in 24 (6%) 
patients remained Unfavorable 
median OS 3.9 months. CTC in 74 
(17%) patients converted to 
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Favorable CTC median OS 11.7 month and CTC converted to Unfavorable in 29 (7%)
patients median OS 7.1 month. CTC in 88 (38%) prostate cancer patients remained
Favorable median OS of more than 26 months, CTC in 71 (31%) patients remained
Unfavorable median OS 6.8 months, CTC in 45 (20%) patients converted to
Favorable CTC median OS 21.3 month and CTC converted to Unfavorable in 26
(11%) patients median OS 9.3 month.
Disease evaluation after initiation of therapy in patients with metastatic
carcinoma is performed by radiographic imaging of the disease in those
patients that have measurable lesions. Changes in tumor size and
appearances of new lesions can only be determined after 3 to 6 months of
therapy. The question that arises is whether the disease assessment by
radiographic imaging provides similar results when compared to
measurement of CTC or are these two different biological phenomenons,
Figure 21.
Figure 21 Measurement of disease burden by radiographic imaging (A) versus 
tumor cells in peripheral blood (B)
Comparison of CTC and radiographic imaging to predict survival in patients
with metastatic breast cancer clearly show that they are two independent
measurements of disease activity 56. The Kaplan Meier analysis in Figure 22
shows that the patients with progressive disease by radiographic imaging
and Unfavorable CTC after initiation of therapy have the worst prognosis.
Conversely patients with stable disease or a partial response of the disease
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by radiographic imaging and Favorable CTC have the best prognosis. In 21%
of these cases both technologies did not agree, those patients that did
progress by radiographic imaging but Favorable CTC had a survival not
statistical different from patients with no progressive disease by imaging.
Conversely patients with no progression by radiographic imaging but
Unfavorable CTC had a survival not statistically different from those that
showed progressive disease by imaging. Disease assessment by CTC reflects
the biological activity and the  aggressiveness of the disease more accurately.
Figure 22 Measurement of the change in disease burden by radiographic imaging 
at the first disease evaluation versus CTC at the first follow-up after 
initiation of therapy and its relation to survival in patients with 
measurable metastatic breast cancer. S/PR = stable disease / partial 
response, PD = progressive disease by radiographic imaging
In those cases where no measurable lesions were present, proteins shed by
the tumor were measured, these serum tumor markers are however not
being produced by all tumors and one can never assess whether they are
produced by a few or many cancer cells. Moreover, most of these proteins are
also produced by normal cells and thus are present in serum of healthy
individuals. In most cases measurable liver lesions are present in colorectal
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cancer, but in breast cancer approximately 30% of the patients have non-
measurable disease, and in prostate cancer only few cases have measurable
disease.
Challenges
Improvements in circulating tumor cell detection
The data obtained to date suggests that the mere presence of CTC drastically
changes the survival prospects of patients with metastatic carcinomas. The
technology challenge is to assure that the events detected are indeed tumor
cells. Evaluation of the errors in CTC identification pointed to the ability of
the operator to assign an event as a CTC 60. Future CTC assignment therefore
will need to be independent of the operator. This is of greatest importance
when “tumor cells” are detected in blood of patients with no evidence of
active disease. A good reason to make CTC assignment independent of the
operator. Although the analysis of larger blood volumes can help to improve
the accuracy of CTC detection the volume one can reasonably draw, quickly
reaches its limit.
A first step to increase the specificity of the test was the demonstration that
tumor cells in blood showed the same chromosomal abnormalities as those
present in the primary tumor 61. To enable the detection of abnormal
chromosome copy in, technology was developed to preserve the cells in the
chamber after they have been analyzed 62. Samples could now be hybridized
with fluorescence labeled nucleic acid probes and the copy number of each
probe could be assessed after revisiting the locations of the CTC in the
analysis chamber. Figure 23 shows the enumeration of the number of copies
of chromosome 1, 7, 8 and 17 in an event previously identified as a CTC.
Although these four chromosomes are the ones that are most frequently
affected in the major carcinomas many other abnormalities can be present
that will go undetected with this approach. The aim therefore is to
drastically improve the number of probes we can assess. This challenge is
subject of the PhD project of Sjoerd Ligthart. Sjoerd’s simulation in Figure 24
shows the packing of all 23 chromosome pairs identified with FISH probes
providing a 650nm fluorescent signal in a 10 µm cell. I am real curious to
see how far this simulation is from the one he is going to show us when he
is ready to defend his thesis. Who knows he might exploit his observation on
the cover of this booklet. In this picture, the cell has been permeabilized
causing the DNA to leak out of the cell providing a larger surface to
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investigate the composition of the DNA.
Analysis of a large number of CTC by FISH showed that some of the events
identified as CTC did not show any FISH signals. The review of the
morphology of these events suggested that they were undergoing apoptosis.
Improvement of the discrimination within the events considered as CTC is
needed. A first step towards this was achieved by the PhD candidate Eric
Schreuder. During his PhD project he made an image cytometer with a
higher resolution and improved ability to quantify the signals from the cells.
Panel A in Figure 25 illustrates a typical measurement of an
immunomagnetically enriched and fluorescently labeled blood sample from
a patient with metastatic cancer performed with Eric’s cytometer. The CTC
candidates are represented in the scatter plot comparing the fluorescence
intensity of the nucleic dye DAPI and Cytokeratin PE divided by CD45 APC.
The red dots were identified as “intact” tumor cells by examination of their
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Figure 23 Panel A shows an image of a nucleus (DAPI), the staining of 
Cytokeratin-PE of an event identified as a CTC. No signals were 
observed in the FITC image and the CD45APC image. After preserving 
the sample and Fluorescence In-Situ Hybridization (FISH) with fluores-
cently labeled probes identifying the centromeres of chromosome 1, 7, 8 
and 17 the system revisited the original location of the CTC in the 
original analysis chamber, Panel B. The CTC was aneuploid as verified 
by the presence of three copies of chromosome 7, 4 of chromosome 8 and 
a normal copy number 2 for chromosome 1 and 17.
Experiments by Joost Swennenhuis, Ronald Sipkema and Arjan Tibbe.
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morphology, the green dots as CTC undergoing apoptosis visualized by
clumping of cytokeratin and the purple dots as CTC debris. The blue dots are
identified as leukocytes that either stain non-specific with cytokeratin or
stain because they have taken up tumor cell debris through phagocytosis,
and the grey dots represent artifacts. Three representative images are
illustrated on top of the panel. The analysis of blood samples from 26
metastatic cancer patients showed a clear relation between the presence of
CTC and CTC debris with more debris detected than intact CTC, panel B.
Patients with no intact CTC detected did not have CTC debris. This
observation suggests that development of technology that reliably
enumerates tumor cell derived microparticles, could be a useful tool to
monitor the disease in patients treated for cancer.
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Figure 24 Computer simulation 23 chromosome probes identified by 650nm FISH 
probes in a 10 µm cell. Simulation by Sjoerd Ligthart.
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Figure 25 Measurement after immunomagnetic enrichment and fluorescent 
labeling of CTC from 7.5 mL of blood, Panel A. The arrow indicates the 
transition from intact CTC to tumor cell debris. Panel B shows the 
correlation between the number of intact CTC and CTC debris in 26 
metastatic cancer patients. Experiments by Eric Schreuder.
A drawback of the immunomagnetic enrichment is that along with CTC, the
ferrofluids not bound to the cells come along for the ride. The larger the
blood volume, the more ferrofluids will be concentrated on the analysis
surface. Ferrofluids are colloidal and the automated sample preparation
device allows cells to settle under the influence of gravity after which the
top layer of the sample can be aspirated without removing the cells. This
reduction is not sufficient, ferrofluids still mask portions of the cells
interfering with the quality of the image and decrease the fluorescence
signals. Improving the ability of the detection system does not overcome this
problem. The challenge for Tycho Scholten in his PhD project is to tackle this
issue. Tycho has designed a new surface for the analysis chamber which is
made from polydimethylsiloxane (PDMS). These PDMS structures contain
channels in which cells are moved under the influence of the vertical
magnetic gradients. The reduction in the scanning area provide a three fold
reduction in the analysis time, but he also made his problem larger by
increasing the amount of ferrofluids. Panel A of Figure 26 shows a Smooth
Electronic Microscope (SEM) image of the PDMS structure. The obstruction of
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the CTC analysis by the ferrofluid can be observed in Panel B, which shows
one of the channels with three leukocytes (blue) and one CTC (green). The
horizontal black lines are created by the alignment of 170nm ferrofluids
under influence of the magnetic field. Panel C shows one of the early
successes from Tycho in which he was able to reduce the ferrofluids while
maintaining the CTC. Two green colored CTC, a couple of blue colored
leukocytes, some uncolored erythrocytes and a significant reduction of the
ferrofluids can be observed. The small objects, frequently associated with the
ferrofluids represent platelets or tumor cell derived microparticles. It is
obvious that more information can be retrieved from the image shown in
Panel C as compared to the image in Panel B.
Figure 26 Panel A, SEM image of the CTC analysis surface. The two sided arrow 
indicates the width of the analysis channel and the vertical arrow 
indicates the adjacent surface that aids the movement of the cells in the 
analysis channel. Panel B, analysis channel with ferrofluids a CTC 
(green) and leukocytes (blue). Panel C, analysis channel after ferrofluid 
reduction with two CTC, leukocytes, erythrocytes and platelets.
Experiments by Tycho Scholten.
This is a big step, but if we look at all the results we have obtained and think
about the approach we have taken, it can not lead to the ultimate solution.
We are only taking a 0.15% aliquot from the total blood volume and simply
can not analyze all the blood nor can we detect the presence of all the tumor
cells that may hide elsewhere in the body and can awake, proliferate and
then disseminate at any time. The challenge is to identify and develop
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technology that is capable to interrogate all the blood for the presence of
tumor cells. A breakthrough would be if the technology also could eliminate
the tumor cells. Identification and elimination of dormant tumor cells will
be a greater challenge as little is known about them. What we do know is
that they do matter, can hide in the body for prolonged periods of time and
occasionally can be found in the blood 63,64,65. Time will tell whether the
University of Twente will make an impact in this field of research. The
initiative by the University of Twente to introduce Technical Medicine as a
new interdisciplinary program linking basic science and technology with
clinical practice in medicine certainly sets the stage for this to happen. It
may well be that some of the basic science currently worked on at the
university will provide valuable tools for our challenge. Who knows it may be
in-vivo imaging technologies applied on chicken eggs in the group lead by
Prof Ton van Leeuwen or the micro-bubble technology  worked on in the
group lead by Prof Detlef Lohse.
Personalized Medicine
The oncologist will have an increasing armamentarium of therapies
available to treat patients with recurrent cancer and is faced with the
challenge of finding the most effective treatment for the individual patient.
The paradigm shift towards targeted therapy will end the unrealistic attempt
to kill all cancer cells with high-dose chemotherapy, but also complicates
matters as more knowledge is required on the characteristics of the tumor in
the individual patient. In current medical practice the absence or presence of
treatment targets is assessed on the primary tumor. It is however well-
documented that the original tumor clone is genetically unstable and
continues to mutate at a rapid rate constantly giving rise to variants
resistant to the particular therapeutic regimen 66-74. To overcome this issue
assessment of therapy targets can be performed on CTC and would
constitute a “real-time” biopsy. First attempts have been successful and
promise to be valuable tools for the development of targeted therapies 75-80.
Figure 27 shows examples of assessments of therapy targets on CTC by
investigating the presence of the target protein or the amplification of its
gene.
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Figure 27 Assessment of therapy targets on CTC. Panel A, two CTC from a breast 
cancer patient one CTC expresses bcl-2, but the other CTC does not.
Panel B, CTC from a breast cancer patient expressing the Her2 protein
and in Panel D a CTC with overamplification of the Her2 gene. Panel C,
CTC in a prostate cancer patient with overamplification of the Androgen 
receptor and no translocation of TMPRSS/ERG.
The ability to detect the presence of a therapeutic target may not be
sufficient and we may need to visualize therapeutic pathways within the
cells to determine whether or not the drug indeed will initiate the cascade of
events necessary to lead to the death of the tumor cells. Under the
leadership of Prof Jan Greve  the University of Twente made significant
contributions to the field of optical detection technology. At the time I
started my PhD work in his department, Cees Otto was working on Raman
spectroscopy and showed me spectra in which he pointed out signals
produced by water and silver molecules in the solution he was investigating.
At the time I could not envision what this could bring to the table for the
advancement of medicine. Looking back, my time frame in which I expect
things to happen was to short, as now 20 years later, Raman spectroscopy
can be used to characterize cells and I am in active discussions with Cees to
explore its potential to visualize molecules and organelles in tumor cells. To
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evaluate whether there is merit to this approach a Raman spectrum was
measured from white blood cells labeled with an Allophycocyan conjugated
antibody recognizing CD8. Individual leukocytes were located by bright field
microscopy for Raman imaging of the cells. Some cells yielded a Raman
spectrum Cees never encountered, Figure 28. The unique spectrum most
likely can be contributed to Allophycocyan the fluorescent label tagged onto
a CD8+ lymphocyte. It definitely aroused my curiosity and I fully expect that
we will merge the technologies we both developed. We hope to map the
Raman signals from immunophenotypically defined cells, during their
maturation and proliferation pathways, and than compare those with
cancerous cells.
Figure 28 Ramanspectrum of an Allophycocyan labeled CD8+ lymphocyte 
collected after a 10 second accumulation with 2mW power from a 
647nm laser line. Experiment by Henk-Jan van Manen.
Not only do we need to develop technology which obtains more detailed
information from the detected cells we will also need technology that can
assess the presence and functional status of the complete arsenal of
Ki
jk
en
 D
en
ke
n 
D
oe
n 
(L
oo
k 
Th
in
k 
D
o)
Raman shift(cm-1)
070903 Oratieboekje Terstappen  19-09-2007  16:59  Pagina 38
39
therapeutic targets on each cell. Technology residing within the University of
Twente’s institute of nanotechnology (MESA+) may well be suited to tackle this
problem. Discussions with Prof Albert van der Berg lead to a concept we
baptized the “Cancer Cell Chip”, Figure 29. Whether this concept is viable
may be examined in future bachelors, masters and PhD assignments. First
experiments conducted by Floor Wolbers and Tycho Scholten indicate, that the
challenges the students will face are not trivial. This however makes science
exciting and when we provide the students with a sound education they too
will enjoy the great feeling of uncovering answers to a problem after they have
taken a good look at a problem, arrived at an experimental plan by thoroughly
thinking about the problem and than carefully execute the plan (do).
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Figure 29 “Cancer Cell Chip” a bright field image of cells from the breast cancer 
cell line MCF7 moved into individual positions in a microfluidic device 
(indicated with arrows). Experiment by Floor Wolbers and Tycho 
Scholten. Subsequent deliveries of therapeutic target specific probes or 
movement of the cells to the locations of the probes will be needed.
The number of probes that can be detected simultaneously is limited 
and technology will be needed to remove the previously used probes.
For functional analysis the viability of the cells will need to be main-
tained which might be achieved by electroporation.
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Divergence 
Curiosity is a necessary evil in science as at one hand it’s the key ingredient
for new discoveries, but at the other hand it unavoidably leads to deviations
from the main course as well as troubles at the home front as one tends to
lose track of time. It happened to me shortly after I started my PhD
assignment, but had a good excuse as my supervisor the late Prof Bart de
Grooth was of a similar mind. We quickly learned to harmonize each others
skills and spend for example many evenings trying out techniques to
measure the eating capabilities of granulocytes. I never have been able to
avoid this temptation, after phagocytosis 81, it was primary paroxysmal
nocturnal hemoglobinuria 82, then bone development 83, then development
of a technology to identify specific human monoclonal antibody fragments
from a synthetic phage antibody library 84, then gene therapy 85 and those in
the audience reading the local news paper have already been made aware of
the latest deviation from the main course,
Figure 30.
Figure 30 Affordable HIV monitoring in 
resource poor countries86-88.
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When asked by journalists whether they could talk to the bachelor students
working on the project I suggested they interview my room mate Prof Jan
Greve as he was the one who initiated the project and was more familiar
with the real status of the project. Indeed progress has been made on this
STW funded project and PhD student Xiao Li (Lilly) has successfully
evaluated the assay in Thailand this summer on the instrument designed
and built by Aurel Ymeti and Christian Breukers. A more appropriate
heading of the article would have been: UT-discovery might help the third
world.
We have come to the end of this lecture and hope it created the excitement
required to get you all thinking of how to advance the cancer field. Many of
you have probably experienced the far reaching implications when someone
in your environment is diagnosed with cancer and if we just try a little
harder to work together we will make an impact. So in plain US terminology,
let’s kick butt.
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principals would not hamper me in becoming a succesfull scientist. After
being diagnosed with an incurable cancer, Bart tried to put together the
content of his inaugural lecture, the tittle would have been “De Wekker”
(Alarm Clock), Bart was facinated with the perfect mechanics of a clock and
on the other hand he realized, that his clock was about to stop ticking. This
was one more reason to work dilligently to advance the cancer field. Jan
Greve, Bart and myself started the “Cell Characterization Group” at the
department of Applied Physics in the early eighties (with no resources
besides some gray matter). Since Jan’s official retirement he reminded me
from time to time that the Cell Characterization Group would come to an
end at the Univerity of Twente if no plans for its future were made.
Discussions with Vinod, Cees and Ton confirmed that nobody had the time
nor sufficient knowledge to keep the group alive. All eyes pointed at me, but
I was living and working in the USA. Luckily, Alfred Bliek the dean of the
faculty of Science and Technology at the University of Twente and Byron
Hewett the Chief Operating Officer at Immunicon corporation have had quite
some experience in commuting. They believed it could work, so  here I stand.
“Once an apprentice always an apprentice” another reminder from Jan
Greve, this apprentice took some of his advice quite seriously. “You need to
go to the USA to broaden your horizon”. I was happy to procure a post-doc
position under the tutelage of Michael Loken in sunny Palo Alto, California.
That environment was indeed stimulating and many people helped me do
some exciting science. I lost track of time and spent many, many more years
than originally planned. One day I met Paul Liberti, a Professor in
Biochemistry at the Thomas Jefferson University in Philadelphia who had
started a company around ferrofluids. He promised me that I could take the
company in any direction I liked, and so the cancer story started. Initially I
only got the dentist Jerry Doyle believing and helping, followed by software
guru John Sylvia and steadily more people jumped on the bandwagon as
proof of principles were demonstrated. Financing is a necessary evil, two
topnotch finance dudes Jim Murphy and Ed Erickson raised the funds
required to allow the science to mature, conduct the clinical studies and
develop and manufacture the products. Multi-tasking is a skill I mastered
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over the years, but it would have left me empty handed when I would not
have been surrounded by an excellent team of people. As we speak Craig
Miller is most likely sitting behind his desk crunching data, Madeline
Repollet is guiding her team processing and analyzing blood samples from
cancer patients, Mark Connely and Chandra Rao are guiding a team
extracting more information from cancer cells and the teams from John
Verrant, Frank Coumans and Mike Kagan are trying to make the necessary
adjustments to the instrumentation. The european Immunicon crew headed
up by Arjan Tibbe and the current members of the “Cell Characterization
Group” are in the audience and believe me they are great to work with. So if
you are interested in joining the effort please feel free to contact any of us.
When we will leave this room I will again have to ask Yvonne Greve the
honory member of the “Cell Characterization Group” permission to let her
dear husband Jan spend some time with us in advancing the field.
Last but not least I would like to dedicate this lecture to my parents Corry
and Guus and to my “girlfriend” Jessy, mother of our children Wout, Jon and
Stijn who has been supportive throughout this endeavor.
Ik heb gezegd
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